Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold”

PDS Biotechnology (NASDAQ:PDSB) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

PDSB has been the subject of several other research reports. Weiss Ratings downgraded PDS Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 11th. HC Wainwright restated a “buy” rating on shares of PDS Biotechnology in a research report on Wednesday, August 26th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

PDSB stock opened at $0.81 on Friday. The company has a debt-to-equity ratio of 2.73, a current ratio of 0.57 and a quick ratio of 0.57. The company’s 50 day simple moving average is $0.49 and its 200-day simple moving average is $0.78. PDS Biotechnology has a 12 month low of $0.20 and a 12 month high of $1.55. The firm has a market capitalization of $45.08 million, a PE ratio of -1.26 and a beta of 1.46.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Equities analysts expect that PDS Biotechnology will post -0.49 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of PDS Biotechnology during the 2nd quarter worth $535,000. Bank of New York Mellon Corp acquired a new stake in shares of PDS Biotechnology during the second quarter worth $60,000. Finally, Renaissance Technologies LLC grew its position in shares of PDS Biotechnology by 25.0% in the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after purchasing an additional 44,100 shares during the period. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.